Engineered immune cells aim to tame stubborn autoimmune diseases
NCT ID NCT07490275
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage trial tests a one-time infusion of donor immune cells (CAR-γδT cells) designed to target and destroy faulty B cells in people with severe autoimmune diseases like lupus and scleroderma. The main goal is to check safety and find the right dose in 9 adults whose disease has not responded to standard treatments. This approach aims to control the disease rather than provide a cure, as long-term effects are still unknown.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for INFLAMMATORY MYOPATHY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••